Skip to main content

Table 2 Sokal, Hasford, and EUTOS Systems[1315]

From: Biomarkers for determining the prognosis in chronic myelogenous leukemia

  Sokal Hasford (EURO) EUTOS
Year introduced 1984 1998 2011
Predominant treatment modality Conventional chemotherapy Interferon-α–based regimens Imatinib
Factors •Age •Age •Spleen size
•Spleen size •Spleen size •Basophil count
•Platelet count •Platelet count
•Percentage of blasts •Percentage of blasts
•Percentage of basophils
•Percentage of eosinophils
Calculation of score Exp 0.0116 (age – 43) + 0 .0345 (spleen size [cm below costal margin] – 7.5 cm) + 0.188 [(platelet count/700)2 – 0.563] + 0.0887 (% blasts in blood – 2.1) (0.6666 × age [0 when age <50 years; 1, otherwise] + 0.0420 × spleen size [cm below costal margin] + 0.0584 × blasts [%] + 0.0413 × eosinophils [%] + 0.2039 × basophils [0 when basophils <3%; 1, otherwise] + 1.0956 × platelet count [0 when platelets <1500 × 109/L; 1, otherwise]) × 1000 7 × basophils + 4 × spleen size
Risk groupsa •High: score > 1.2 •High: score >1480 •High: score > 87
•Intermediate: score 0.8-1.2 •Intermediate: score >780 and ≤1480 •Low: score ≤ 87
•Low: score < 0.8 •Low: score ≤ 780
  1. aAn intermediate risk category is not defined for EUTOS.